

IN THE UNITED STATES DISTRICT COURT
FOR THE DISTRICT OF DELAWARE

In re Entresto (Sacubitril/Valsartan) Patent
Litigation

No. 20-md-2930-RGA

NOVARTIS PHARMACEUTICALS CORP.,

Plaintiff,

v.

C.A. No. 21-1347-RGA

C.A. No. 21-1797-RGA

CRYSTAL PHARMACEUTICAL
(SUZHOU) CO., LTD.,


Defendant.

ORDER

For the reasons stated in the corresponding Memorandum Opinion, Plaintiff's motions to dismiss Plaintiff's complaints against Defendant and Defendant's counterclaims against Plaintiff's U.S. Patents Nos. 9,517,226, 9,937,143, and 11,135,192 (C.A. No. 21-1347, D.I. 23; C.A. No. 21-1797, D.I. 22) are **GRANTED**. The complaints and counterclaims are **DISMISSED** without prejudice.

IT IS SO ORDERED.

Entered this 14th day of November, 2022.


United States District Judge